[1] Lee JM,Ahn SH,Kim HS,et al.Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.Hepatolo gy,2011,53:1486-1493.
[2] 吴国春,成兆军,王雄,等.恩替卡韦治疗慢性乙型肝炎后病毒学反弹与HBsAg水平的关系.江苏医药,2011,37:2072-2073.
[3] 李瑞,李新艳.慢性乙型肝炎恩替卡韦治疗结束后病毒学反弹与乙型肝炎表面抗原水平的关系.肝脏,2017,22:723-726.
[4] 隋洪华,徐永红,刘涵云,等.恩替卡韦治疗慢性乙型肝炎过程中应答不佳相关因素分析.胃肠病学与肝病学杂志,2014,23:323-327.
[5] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版).中华肝脏病杂志,2015,23:888-905.
[6] 参加乙型肝炎病毒耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理.中华肝脏病杂志,2013,21:15-22.
[7] 徐京杭,于岩岩,斯崇文,等.马来酸恩替卡韦片治疗HBeAg阴性慢性乙型肝炎的随机、双盲、双模拟对照、多中心临床研究48周结果.中华肝脏病杂志,2012,20:512-515.
[8] Deguchi M, Yamashita N, Kagita M, et a1. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods, 2004, 115:217-222.
[9] Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology,2004,126:1750-1758.
[10] Warsthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA declne and HBsAg reduction in patients with chronic hepatitis B, Hepatology, 2006,44:675-684.
[11] Chan HL,Wong VW,Tse AM,et a1. Serum hepatitis B surface antigen qua ntitafion can reflect Hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol, 2007, 5:1462-1468.
[12] Brunetto MR. A new role for an old marker, HBsAg. J Hepatol,2010, 52: 475-477. |
